Bioprosthetic Valve Thrombosis and Obstruction Secondary to COVID-19
Autor: | Jose Leandro Perez Bosca, Guillem Llopis Gisbert, Rafael Payá Serrano, Andrés M. Cubillos Arango, Miguel A. Moruno Benita, Ana Payá Chaume, Alberto Berenguer Jofresa, Verónica Vidal Urrutia |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19) business.industry Case Report 030204 cardiovascular system & hematology medicine.disease Thrombosis Surgery Pulmonary embolism 03 medical and health sciences Stenosis 0302 clinical medicine medicine.anatomical_structure Mitral valve stenosis Mitral valve medicine 030212 general & internal medicine Thrombus Cardiology and Cardiovascular Medicine business Complication |
Zdroj: | Canadian Journal of Cardiology The Canadian Journal of Cardiology |
ISSN: | 0828-282X |
DOI: | 10.1016/j.cjca.2020.10.008 |
Popis: | Patients with COVID-19 may present a hypercoagulable state, with an important impact on morbidity and mortality. Because of this situation pulmonary embolism is a frequent complication during the course of infection. We present the case of a patient recently discharged, after admission with confirmed COVID-19, who developed a pulmonary embolism and thrombosis of a biological mitral valve prosthesis, producing valve obstruction and stenosis. After 15 days of anticoagulant treatment, resolution of the thrombus and normalization of prosthetic valve function was observed. This case supports current recommendations of administering full-dose anticoagulation therapy to COVID-19 patients with biological heart valve prosthesis, even after the acute phase of infection. We present the case of a patient who developed a pulmonary embolism and thrombosis of a biological mitral valve prosthesis, during recovery from COVID-19 infection. Our findings supports the recommendation of a prolonged anticoagulation strategy at full therapeutic doses in COVID-19 patients with biological heart valve prosthesis. |
Databáze: | OpenAIRE |
Externí odkaz: |